The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Novel CAR-T products in the pipeline for multiple myeloma
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses novel CAR-T products that are under investigation for the treatment of multiple myeloma. He mentions CART-ddBCMA, dual-binding CAR-Ts targeting both BCMA and CD19, and homegrown CAR-Ts being developed in smaller research labs. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: BMS, Janssen, Sanofi Consultant: Pfizer, GSK
